JOJoanne O'DWyer

Joanne O'DWyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanne O'DWyer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding the Impact of Reperfusion in the Development of a Safe Compression Therapy

    by Rachel Beatty, Pascal Paco Farina, Joanne O’dWyer, Peter Dockery, Alanna Stanley

    The benefits of an intermittent compression therapy are known; however, in some circumstances, it results in soft-tissue injuries. This study aims to create a model for testing the safety, efficacy, and molecular mechanisms of a compression therapy, without creating an injury. Existing ischemia/reperfusion protocols were modified to apply repeated compression without forming a pressure ulcer. The skin of immobilized C57BL/6 male mice was pinched between two magnets (3 h, 2–3 days of recovery between treatments). Hair growth was stunted but started to regrow within 18 days. The application of pressure caused an increase in epidermal thickness (****p = 0.002), CD31+ total number (**p = 0.0021), and increased radial diffusion distance (*p = 0.0285). Pressure caused a reduction in adipocyte volume weight mean volume (****p < 0.0001) and CD34 volume fraction (*p = 0.0460). Stem cell populations (cytokeratin 15; p = 0.4992, CD34; p = 0.6873 and integrin α-6; p = 0.7752) were unaffected. Importantly, pressure did not increase markers of DNA damage (p53; p = 0.7524 and caspase 3; p = 0.0839), indicating that this compression model had limited negative effects on the tissue. The altered protocol successfully created a model to permit the analysis of uninjured skin after pressure is applied.


  • Open Access

    Evaluation of adipose-derived stromal cell infused modified-hyaluronic acid scaffolds for post cancer breast reconstruction

    by Ritihaas Surya Challapalli, Joanne O’DWyer, Niall McInerney, Michael J Kerin, Garry P Duffy, Eimear B Dolan, Roisin M Dwyer, Aoife J Lowery

    Introduction: Primary breast cancer surgery can compromise aesthetics and quality-of-life for breast cancer patients. While breast reconstruction improves these outcomes, current methods are limited by suboptimal aesthetic outcomes and potential complication risks. There is an urgent clinical need for improved approaches to post surgical reconstruction for breast cancer patients. Adipose-derived stromal cells (ADSCs) with biological scaffolds are being widely evaluated for tissue engineering applications in the field of reconstruction. Aims: This study aimed to assess the biomechanical properties, biocompatibility, adipogenic potential of ADSCs encapsulated in modified hyaluronic acid derivatives in vitro; and efficacy and tissue integration of this construct in vivo in a murine breast cancer and reconstruction model. Methods: ADSCs were obtained, with informed consent, from female breast cancer patients undergoing autologous breast reconstruction or cosmetic procedures (n=8) aged 47±12 years. Modified hyaluronic acid solution was combined with 1×10 6 ADSCs/mL and crosslinked using hydrogen peroxide and horseradish peroxidase. Young’s modulus, cell viability and adipogenic potential of the cell-loaded hydrogels were assessed in vitro. In vivo, hydrogels combined with murine ADSCs were grafted into a murine breast cancer model and tissues were harvested for immunohistochemistry after 4 weeks. Results: ADSCs were characterised via morphology, Colony forming unit-fibroblast (CFU-F) assay, flow cytometry and multilineage differentiation. The cell-loaded hydrogels had a compressive Young’s modulus of 7.35±0.96 kPa after 21 days in culture, similar to human breast adipose tissue (∼10 kPa). High ADSC viability was observed after 21 days in culture, and ADSCs differentiated into mature adipocytes. After 4 weeks in vivo, hydrogels exhibited adipocytes, vascular endothelium, and pericyte-like cells. Conclusion: This study demonstrates the potential suitability of modified hyaluronic acid hydrogels encapsulating ADSCs for adipose tissue engineering for post breast cancer reconstruction.


  • Open Access

    Actuation‐Mediated Compression of a Mechanoresponsive Hydrogel by Soft Robotics to Control Release of Therapeutic Proteins

    by Eimear J. Wallace, Joanne O'DWyer, Eimear B. Dolan, Liam P. Burke, Robert Wylie, Gabriella Bellavia, Stefania Straino, Francesca Cianfarani, Gabriella Ciotti, Simona Serini, et al.

    Therapeutic proteins, the fastest growing class of pharmaceuticals, are subject to rapid proteolytic degradation in vivo, rendering them inactive. Sophisticated drug delivery systems that maintain protein stability, prolong therapeutic effects, and reduce administration frequency are urgently required. Herein, a mechanoresponsive hydrogel is developed contained within a soft robotic drug delivery (SRDD) device. In a step‐change from previously reported systems, pneumatic actuation of this system releases the cationic therapeutic protein Vascular Endothelial Growth Factor (VEGF) in a bioactive form which is required for therapeutic angiogenesis, the growth of new blood vessels, in numerous clinical conditions. The ability of the SRDD device to release bioactive VEGF in a spatiotemporal manner from the hydrogel is tested in diabetic rats – a model in which angiogenesis is difficult to stimulate. Daily actuation of the SRDD device in the diabetic rat model significantly increased cluster of differentiation 31+ (CD31+) blood vessel number (p = 0.0335) and the diameter of alpha‐smooth muscle actin+ (α‐SMA+) blood vessels (p = 0.0025) compared to passive release of VEGF from non‐actuated devices. The SRDD device combined with the mechanoresponsive hydrogel offers the potential to deliver an array of bioactive therapeutics in a spatiotemporal manner to mimic their natural release in vivo.


  • Soft robot–mediated autonomous adaptation to fibrotic capsule formation for improved drug delivery

    by Rachel Beatty, Keegan L. Mendez, Lucien H. J. Schreiber, Ruth Tarpey, William Whyte, Yiling Fan, Scott T. Robinson, Joanne O’dWyer, Andrew J. Simpkin, Joseph Tannian, et al.

    The foreign body response impedes the function and longevity of implantable drug delivery devices. As a dense fibrotic capsule forms, integration of the device with the host tissue becomes compromised, ultimately resulting in device seclusion and treatment failure. We present FibroSensing Dynamic Soft Reservoir (FSDSR), an implantable drug delivery device capable of monitoring fibrotic capsule formation and overcoming its effects via soft robotic actuations. Occlusion of the FSDSR porous membrane was monitored over 7 days in a rodent model using electrochemical impedance spectroscopy. The electrical resistance of the fibrotic capsule correlated to its increase in thickness and volume. Our FibroSensing membrane showed great sensitivity in detecting changes at the abiotic/biotic interface, such as collagen deposition and myofibroblast proliferation. The potential of the FSDSR to overcome fibrotic capsule formation and maintain constant drug dosing over time was demonstrated in silico and in vitro. Controlled closed loop release of methylene blue into agarose gels (with a comparable fold change in permeability relating to 7 and 28 days in vivo) was achieved by adjusting the magnitude and frequency of pneumatic actuations after impedance measurements by the FibroSensing membrane. By sensing fibrotic capsule formation in vivo, the FSDSR will be capable of probing and adapting to the foreign body response through dynamic actuation changes. Informed by real-time sensor signals, this device offers the potential for long-term efficacy and sustained drug dosing, even in the setting of fibrotic capsule formation.